Sec Form 13D Filing - Ainos Inc. filing for Ainos, Inc. (AIMD) - 2025-04-09

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
The number of securities in Row 7 includes (i) 2,456,319 shares of common stock, $0.01 par value, of Ainos, Inc., a Texas corporation (the "Issuer"), owned directly by Ainos Inc., a Cayman Islands company ("Ainos KY"), (ii) 4,715,594 shares pursuant to a Voting Agreement dated January 26, 2024 (the "2024 Voting Agreement"), by and among the Reporting Person, and Chun-Hsien Tsai, Ting Chuan Lee, Chun-Jung Tsai, and Chung-Yi Tsai (the "Tsai Group"); (iii) 456,356 shares of common stock pursuant to a Voting Agreement dated March 7, 2024 (the "2024 Voting Agreement II") with Chih-Heng Lu; (iv) 3,148,788 shares pursuant to a Voting Agreement dated May 3, 2024 between Ainos KY and ASE Test, Inc. ("ASE Test" and the "ASE Voting Agreement") (with the 3,148,788 ASE Test shares consisting of the following (a) 29,411 shares owned by ASE Test, (b) 499,377 shares issuable to ASE Test upon conversion of outstanding convertible notes of the Issuer (c) 2,120,000 shares issuable to ASE Test upon conversion of a convertible note of the Issuer issuable within 60 days), and (d) 500,000 shares issuable to ASE Test upon exercise of warrants to purchase 500,000 shares of the Issuer with ASE Test, (v) 5,500,000 shares pursuant to a Voting Agreement dated August 15, 2024 between Ainos KY and Taiwan Carbon Nano Technology Corporation, and (vi) 276,376 shares pursuant to a Voting Agreement dated March 10, 2025 between Ainos KY and Hsin-Liang Lee (the "2025 Voting Agreement").The numbers in Rows 9, 11 and 13 represents beneficial ownership of 2,456,319 shares of common stock of the Issuer, consisting of 2,456,319 shares owned directly by Ainos KY and excludes (i) 4,715,594 shares pursuant to the 2024 Voting Agreement; (ii) 456,356 shares of common stock pursuant to the 2024 Voting Agreement II; (iii) 3,148,788 shares pursuant to the ASE Voting Agreement, (iv) 5,500,000 shares pursuant to a Voting Agreement dated August 15, 2024 between Ainos KY and Taiwan Carbon Nano Technology Corporation, and (v) 276,376 shares pursuant to the 2025 Voting Agreement.The percentage in Row 13 is based on the sum of (i) 15,433,257 shares of Common Stock outstanding as of March 7, 2025 as set forth in the Annual Report on Form 10-K of the Issuer filed with the SEC on March 7, 2025, (ii) 1,752,500 shares of common stock granted and vested on March 10, 2025 as special stock awards, which were approved by the shareholders of Ainos, Inc. on September 27, 2024, (iii) 3,119,377 total shares issuable to ASE Test upon conversion of outstanding convertible note and exercisable warrant of the Issuer, and (iv) 2,700,000 shares of common stock granted and vested on April 8, 2025 under the Ainos, Inc. 2023 Stock Incentive Plan.This Amendment No. 11 to Schedule 13D ("Amendment No. 11") amends and supplements the Schedule 13D dated April 28, 2021 (the "Original Statement"), as amended and restated by Amendment No. 1 dated December 13, 2023, as amended by Amendment No. 2 dated March 8, 2022, Amendment No. 3 dated September 2, 2022, Amendment No. 4 dated August 15, 2023, Amendment No. 5 dated January 29, 2024, Amendment No. 6 dated March 11, 2024, Amendment No. 7 dated May 6, 2024, Amendment No.8 dated August 20, 2024, Amendment No.9 dated November 26, 2024, and Amendment No.10 dated March 12, 2025 (the Original Statement, as so amended shall be known as the "Statement"), with respect to the Common Stock of the Issuer. Unless otherwise indicated, all capitalized terms used herein shall have the same meaning as set forth in the Statement.Except as set forth below, there are no changes to the information set forth in the Statement.Items 2, 3, 4, 5 and 6 of the Statement are hereby amended as follows:


SCHEDULE 13D

 
Ainos Inc.
 
Signature:/s/ Chun-Hsien Tsai
Name/Title:Chun-Hsien Tsai/Director and CEO
Date:04/09/2025
primary_doc.xml